Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Loncastuximab Tesirine Plus Mosunetuzumab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

NCT05672251 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT05672251
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05672251 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Loncastuximab Tesirine Plus Mosunetuzumab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Lead sponsor
City of Hope Medical Center
Phase
Phase 2
Overall status
Recruiting
Start date
January 2, 2024
Completion date
August 24, 2029
Enrollment
36 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent diffuse large b-cell lymphoma, recurrent grade 3b follicular lymphoma, recurrent high grade b-cell lymphoma, recurrent primary mediastinal (thymic) large b-cell lymphoma, recurrent transformed chronic lymphocytic leukemia, recurrent transformed indolent b-cell non-hodgkin lymphoma to diffuse large b-cell lymphoma, refractory diffuse large b-cell lymphoma, refractory grade 3b follicular lymphoma, refractory high grade b-cell lymphoma, refractory primary mediastinal (thymic) large b-cell lymphoma, refractory transformed chronic lymphocytic leukemia, refractory transformed indolent b-cell non-hodgkin lymphoma to diffuse large b-cell lymphoma